Georg Dahmann

This inventor holds 59 USPTO granted patents and 28 published patent applications, plus 5 CIPO patents and 42 EPO patents, primarily in Pharmaceutical Chemistry (CPC class C07D). Top assignees: Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharma Gmbh & Co Kg, Boehringer Ingelheim Pharmaceuticals, Inc.. Active years: 1998-2026.

USPTO Granted Patents = 59 (Patent Applications = 28)

% Patents Active = 98.3

CIPO Patents = 5 (Patent Applications = 17)

EPO Patents = 42 (Patent Applications = 52)

Average Co-Inventor Count = 7.0

ph-index = 7

Forward Citations = 224(Granted Patents)

Forward Citations (Not Self Cited) = 198(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Ummendorf, DE (1998 - 1999)
Attenweiler, DE (2007 - 2015)
Warthausen-Birkenhard, DE (2014 - 2018)
Biberach an der Riss, DE (2017 - 2022)
Biberach, DE (1998 - 2024)

Company Filing History:

51 out of 1,560

Boehringer Ingelheim International Gmbh

patents

5 out of 194

Boehringer Ingelheim Pharma Gmbh & Co Kg

patents

3 out of 277

Boehringer Ingelheim Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 1998-2026

Loading Chart...

Areas of Expertise:

TRPA1 Inhibitors

EGFR Inhibitors

mGluR5 Modulators

CGRP Antagonists

STING Activators

Fibrotic Diseases

P38 MAP Kinase Inhibitors

Heterocyclic Compounds

Pyrazine Derivatives

Quinolines

Piperazine Derivatives

Thienopyrimidones

59 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655136 - Dioxane derivatives (2026-06-16),

2. 12497401 - Substituted tetrazoles as TRPA1 inhibitors (2025-12-16),

3. 12421218 - Substituted pyrazine-carboxamide derivatives (2025-09-23),

4. 12065427 - Heterocyclic compounds capable of activating STING (2024-08-20),

5. 11878981 - Substituted 1,2,4-oxadiazoles as TRPA1 inhibitors (2024-01-23),

6. 11578080 - Thienopyrimidones (2023-02-14),

7. 11304929 - Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors (2022-04-19),

8. 11174245 - Benzimidazole compounds and derivatives as EGFR inhibitors (2021-11-16),

9. 11136336 - Thienopyrimidones (2021-10-05),

10. 11001570 - 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors (2021-05-11),

11. 10947243 - Heteroaryl SYK inhibitors (2021-03-16),

12. 10849907 - Imidazopyridine derivatives and the use thereof as medicament (2020-12-01),

13. 10155751 - Pyrazolyl-substituted heteroaryls and their use as medicaments (2018-12-18),

14. 10154990 - Medicaments for the treatment or prevention of fibrotic diseases (2018-12-18),

15. 9914735 - Heteroaryl Syk inhibitors (2018-03-13),

Title: The Innovative Mind of Georg Dahmann

Introduction: Georg Dahmann, a brilliant inventor hailing from Attenweiler, Germany, is known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Georg Dahmann's latest patents showcase his expertise in developing cutting-edge solutions for various industries, including renewable energy, healthcare, and transportation.

Career Highlights: Throughout his illustrious career, Georg Dahmann has been at the forefront of innovation, with a keen focus on creating inventions that have the potential to revolutionize the way we live and work. His dedication to pushing the boundaries of what is possible has earned him recognition as a visionary in the world of inventors.

Collaborations: Georg Dahmann has collaborated with leading research institutions, universities, and companies to bring his inventions to life. His ability to work effectively in multidisciplinary teams has led to the successful implementation of his ideas in real-world applications.

Conclusion: In conclusion, Georg Dahmann's passion for innovation, coupled with his technical expertise, has cemented his reputation as a pioneering inventor. His relentless pursuit of excellence continues to inspire the next generation of inventors to push the limits of creativity and ingenuity.